AG
HTGM

Advisor Group’s HTG Molecular Diagnostics, Inc. Common Stock HTGM Stock Holding History

Advisor Group’s Portfolio HTGM Stock Details HTGM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		$1K Sell
6
-24
-80% -$3.25K ﹤0.01% 5243
2019
Q3 		$4K Sell
30
-6
-17% -$1.21K ﹤0.01% 4788
2019
Q2 		$11K Sell
36
-41
-53% -$17.1K ﹤0.01% 4342
2019
Q1 		$35K Hold
77
– – ﹤0.01% 3635
2018
Q4 		$35K Sell
77
-7
-8% -$4.34K ﹤0.01% 3444
2018
Q3 		$77K Buy
84
+78
+1,300% +$51.5K ﹤0.01% 2952
2018
Q2 		$4K Buy
+6
New +$3.92K ﹤0.01% 4494

Other funds holding HTGM

NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
PCM
Perkins Capital Management Wayzata, Minnesota $133M AUM 127.86% 1-Year Est. Return
CPA
Cowen Prime Advisors New York $290M AUM 57.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HWM
HighMark Wealth Management St. Paul, Minnesota $299M AUM 53.01% 1-Year Est. Return
First Manhattan
First Manhattan New York $39.2B AUM 21.04% 1-Year Est. Return

Advisor Group's HTGM Position: Q4 2019 in Review

Advisor Group reduced its HTG Molecular Diagnostics, Inc. Common Stock (HTGM) stake by 80% in Q4 2019, selling an estimated $3.25K and leaving 6 shares worth $1K. The position accounts for ﹤0.01% of the portfolio, ranked #5243.

Advisor Group first reported a position in HTGM in Q2 2018 and has held it in 7 quarters since. The position peaked at $77K in Q3 2018. 27 funds tracked by Wall St. Rank hold HTGM as of Q4 2019.

  • Advisor Group held 6 shares of HTG Molecular Diagnostics, Inc. Common Stock worth $1K as of Q4 2019.
  • Advisor Group sold 24 HTG Molecular Diagnostics, Inc. Common Stock shares in Q4 2019, an estimated $3.25K.
  • HTG Molecular Diagnostics, Inc. Common Stock made up ﹤0.01% of Advisor Group's portfolio in Q4 2019, its #5243 holding.
  • Advisor Group first reported a position in HTG Molecular Diagnostics, Inc. Common Stock in Q2 2018 and has held it in 7 quarters since.
  • Advisor Group's HTG Molecular Diagnostics, Inc. Common Stock position peaked at $77K in Q3 2018.
  • 27 funds tracked by Wall St. Rank held HTG Molecular Diagnostics, Inc. Common Stock as of Q4 2019.

Based on Advisor Group's 13F filing for Q4 2019, filed 12 Feb 2020.